Four papers this year pushed the metabolism story from “important” to “probably the most actionable lever we have in preventing cognitive decline.” They came from different research traditions — pharmacology, basic neuroscience, nutrition, and gut microbiome science — and they ended up pointing at the same place.
Tirzepatide vs semaglutide: the finding we cannot ignore
Ozempic (semaglutide), Mounjaro, and Zepbound (tirzepatide) started as diabetes and weight-loss drugs. The brain-health question is whether they are interchangeable. They are not: semaglutide acts mainly on one hormone receptor, GLP-1, while tirzepatide acts on two, GLP-1 and GIP.
A large real-world study published this year in the Journal of Diabetes and its Complications compared almost 45,000 tirzepatide users with 45,000 semaglutide users, all with type 2 diabetes (da Silva 2026). The researchers carefully matched the two groups on other health factors. Then they tracked who developed mild cognitive impairment, dementia, or Alzheimer’s over the follow-up period.
The tirzepatide group had dramatically lower rates of mild cognitive impairment and dementia than the semaglutide group. The difference was large enough that the authors themselves flagged the paper as a hypothesis-generating finding, not a settled one. Real-world studies like this can be biased by how doctors choose which patient gets which drug, and a number that large demands confirmation from a proper randomized trial.
But there is a biological reason the difference is plausible. The extra hormone receptor tirzepatide hits (GIP) has direct activity in the brain that GLP-1 alone doesn’t fully replicate. A second 2026 paper by Faragó and colleagues (Faragó 2026) showed that these receptors are present on specific brain cells involved in cognition. So the finding is simultaneously too large to take at face value and too biologically coherent to dismiss.
The important caveat comes from EVOKE and EVOKE+, two large phase 3 trials in people with amyloid-confirmed MCI or mild dementia due to Alzheimer’s disease, where oral semaglutide did not slow clinical progression over 104 weeks (Cummings 2026). The trial used MMSE ≥22 as its cognitive floor, which maps roughly to a much lower MoCA than 19, so this was not the same as the early-action threshold we use in clinic. The cleaner conclusion is narrower: GLP-1 and GIP drugs may matter most as metabolic-risk modifiers, not as proven Alzheimer’s treatments once amyloid-positive symptoms are already present.
What this means for you. If you have type 2 diabetes and a family history of dementia, or you carry an APOE ε4 gene variant, or you are in the early stages of cognitive change, the choice between these drugs is not medically neutral. It is reasonable to have a conversation with your doctor about tirzepatide rather than semaglutide in that situation. Both are preferable to leaving type 2 diabetes undertreated if you are at higher cognitive risk. Frame this as prevention, not treatment.
At Rezilir, we think of GLP-1 receptor agonists and related incretin drugs as support alongside diet and exercise when insulin resistance or metabolic syndrome is driving risk, because they can give people a critical jumpstart. If insulin resistance is reversed with food, exercise, sleep, and muscle work, the medication may not need to stay at the same dose or frequency forever.
The MIND diet, reframed
The MIND diet (a hybrid of the Mediterranean and DASH diets, designed specifically for brain health) got a long-awaited piece of follow-up data this year. Voigt and colleagues published the gut microbiome sub-study of the MIND diet randomized trial (Voigt 2026).
The popular assumption, “MIND diet works by reshaping your gut microbes,” is not quite what the data show. In the trial, both the MIND diet and the comparison diet produced changes in the gut microbiome during the first year. But once the researchers accounted for weight loss, insulin improvements, and reduced inflammation, the diet-specific microbiome signal faded. The microbiome was responding to the body’s metabolic improvement, not driving it.
The MIND diet did produce one specific win: a “buffering” effect on gut metabolic pathways during the active weight-loss phase. The control arm showed more disruption, while the MIND arm stayed steadier.
What this means for you. The MIND diet is worth doing, but the reason to do it is clearer now. Its main payoff is metabolic and weight-related: better insulin sensitivity, better blood vessel health, and better weight. Any cognitive benefit likely rides on that metabolic change. “MIND reshapes your gut” is a popular story that the 2026 data doesn’t quite support. “MIND improves your metabolism, and your brain benefits from that” is closer to the truth, and it’s a more useful story to hold.
At Rezilir, we treat changing the gut microbiome as an aspiration, not a guarantee. The feedback loops between brain, gut, metabolism, and food are complex, and the evidence is still coming in. The best first intervention is food: preferably the kind that doesn’t require a label.
Why one diet doesn’t fit every person
A third paper from Patoine and colleagues (Patoine 2026) added an important wrinkle: your baseline gut microbiome predicts how you’ll respond to a diet change. The same diet prescribed to two different people produces different metabolic and cognitive outcomes depending on what their gut looked like to start.
This is consistent with what we see in clinic. Some people respond dramatically to dietary changes, while others barely respond at all. That difference is biology, not willpower, and part of that biology lives in the gut.
What this means in our clinic
Before we argue about supplements with a patient who has cognitive concerns, we run the metabolic workup. That means:
- Measuring fasting insulin and fasting glucose together so we can calculate HOMA-IR, and measuring visceral fat directly when possible.
- Assessing blood vessel health markers.
- Running inflammation markers like hsCRP.
- Screening for sleep apnea, which is common and underdiagnosed and has outsized effects on brain health.
If you have cognitive concerns and a BMI above 30, or visceral obesity, or prediabetes, or known type 2 diabetes, metabolism is the first two visits. Weight-loss drugs, if appropriate, become part of the conversation. A brain-healthy, real-food ketogenic pattern becomes the recommended eating pattern when excess visceral fat or insulin resistance is part of the picture, with weight loss as the named primary goal. Supplements, if any, sit on top of all of that.
References — Part 2
- da Silva AMP, Januário Campos Cardoso L, Batista S, Gonçalves OR, Paranhos T, Teixeira IPS, Guimarães PD, Espinosa Franco B, Cal H, Salles JEN, Perry G, Høilund-Carlsen PF, Santos DH. Tirzepatide versus semaglutide for the prevention of mild cognitive impairment, dementia, and Alzheimer’s disease in type 2 diabetes: A real-world, retrospective cohort study. Journal of Diabetes and its Complications. 2026;40(5):109306. doi: 10.1016/j.jdiacomp.2026.109306
- Faragó N, Kocsis KÁ, Bordé S, Zvara Á, Barzó P, Puskás LG, Tamás G, Csajbók ÉA. Local co-expression of GLP1R and INS in human cortical interneurons. Frontiers in Endocrinology. 2026;17:1788432. doi: 10.3389/fendo.2026.1788432
- Voigt RM, Chaudhary A, Naqib A, Engen PA, Adnan D, Dhana K, Green SJ, Villanueva M, Agarwal P, Barnes LL, Sacks F, Keshavarzian A. Weight loss and metabolic improvements dominate the microbiome response in the MIND diet intervention: a randomized controlled trial. Alzheimer’s & Dementia: Translational Research & Clinical Interventions. 2026;12(2):e70239. doi: 10.1002/trc2.70239
- Patoine C, Sheffler J, Sims T, Gutierrez V, Park G, Mayonu M, Wang B, Nagpal R. Obesity-associated gut microbiome influences diet-induced metabolic and cognitive outcomes in older adults. Gut Microbes Reports. 2026;3(1):2605879. doi: 10.1080/29933935.2025.2605879
- Cummings JL, Atri A, Sano M, Zetterberg H, Scheltens P, Knop FK, Johannsen P, Wichmann CA, Abschneider RM, Leon T, Feldman HH. Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer’s disease (EVOKE and EVOKE+): two phase 3, randomised, placebo-controlled trials. The Lancet. 2026. doi: 10.1016/S0140-6736(26)00459-9
